Condition
Sebaceous Hyperplasia
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.6% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results75% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (3)
P 2 (1)
P 4 (1)
Trial Status
Completed3
Terminated1
Enrolling By Invitation1
Trial Success Rate
75.0%
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06840470Phase 4CompletedPrimary
Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia
NCT04429607Phase 2Enrolling By InvitationPrimary
Treatment of Sebaceous Hyperplasia With PDL and Nd:YAG Versus Erbium:YAG: A Randomized Controlled Trial
NCT04539886Not ApplicableCompleted
Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions
NCT03612570Not ApplicableCompleted
Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia
NCT04253418Not ApplicableTerminatedPrimary
Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization Study
Showing all 5 trials